| The Standard of Care for iTTP Today | Zheng | 2021 | https://www.sciencedirect.com/science/article/pii/S1538783622018633 |
| Emerging Concepts in iTTP | Laghmouchi et al. | 2021 | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.757192/full |
| The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura |Limb et al |2015| https://ashpublications.org/blood/article/125/10/1526/33786/The-role-of-rituximab-in-the-management-of
| Caplacizumab treatment for Acquired Thrombotic Thrombocytopenic Purpura – HERCULES Trial | Scully et al. | 2019 | https://www.nejm.org/doi/full/10.1056/NEJMoa1806311 |
| Recombinant ADAMTS13 in Congenital TTP | Peyvandi et al. | 2023 | https://www.nejm.org/doi/full/10.1056/NEJMoa2314793 |
| Recombinant ADAMTS13 for iTTP | Peyvandi et al. | 2024 |
https://www.nejm.org/doi/abs/10.1056/NEJMoa2402567
| Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura | Bae, S. |2022 | https://www.bloodresearch.or.kr/journal/view.html?uid=2530&vmd=Full&
